Letter to Blood| April 13, 2023 Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma Clinical Trials & Observations Juan Pablo Alderuccio, Juan Pablo Alderuccio Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL https://orcid.org/0000-0002-2690-3377 Search for other works by this author on: This Site PubMed Google Scholar Isildinha M. Reis, Isildinha M. Reis Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FLBiostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Jean L. Koff, Jean L. Koff Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA https://orcid.org/0000-0003-4414-0489 Search for other works by this author on: This Site PubMed Google Scholar Melissa C. Larson, Melissa C. Larson Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN Search for other works by this author on: This Site PubMed Google Scholar Dai Chihara, Dai Chihara Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX https://orcid.org/0000-0002-1153-2294 Search for other works by this author on: This Site PubMed Google Scholar Wei Zhao, Wei Zhao Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Sara Haddadi, Sara Haddadi Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Thomas M. Habermann, Thomas M. Habermann Division of Hematology, Mayo Clinic, Rochester, MN Search for other works by this author on: This Site PubMed Google Scholar Peter Martin, Peter Martin Division of Hematology/Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY Search for other works by this author on: This Site PubMed Google Scholar Jennifer R. Chapman, Jennifer R. Chapman Department of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Christopher Strouse, Christopher Strouse Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA Search for other works by this author on: This Site PubMed Google Scholar Brad S. Kahl, Brad S. Kahl Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO https://orcid.org/0000-0003-0459-6609 Search for other works by this author on: This Site PubMed Google Scholar Jonathon B. Cohen, Jonathon B. Cohen Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA https://orcid.org/0000-0002-2723-6481 Search for other works by this author on: This Site PubMed Google Scholar Jonathan W. Friedberg, Jonathan W. Friedberg Division of Hematology/Oncology, University of Rochester, Rochester, NY Search for other works by this author on: This Site PubMed Google Scholar James R. Cerhan, James R. Cerhan Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN https://orcid.org/0000-0002-7482-178X Search for other works by this author on: This Site PubMed Google Scholar Christopher R. Flowers, Christopher R. Flowers Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Search for other works by this author on: This Site PubMed Google Scholar Izidore S. Lossos Izidore S. Lossos Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL https://orcid.org/0000-0002-9346-9013 Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (15): 1888–1893. https://doi.org/10.1182/blood.2022019294 Article history Submitted: December 2, 2022 Accepted: January 25, 2023 Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos; Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 2023; 141 (15): 1888–1893. doi: https://doi.org/10.1182/blood.2022019294 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia TO THE EDITOR: Bone marrow (BM) involvement impacts stage and prognosis in lymphoma, remaining an important factor in risk-stratification scores.1,2 Positron emission tomography (PET)/computed tomography (CT) has demonstrated high sensitivity to detect focal skeletal lesions compatible with BM involvement in patients with Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), obviating confirmatory biopsies in most patients.3-5 PET/CT is commonly integrated in the staging workup and assessment of treatment response across different lymphomas, though the ability of fluorodeoxyglucose (FDG) avidity to detect marginal zone lymphoma (MZL) remains questionable.6-8 Furthermore, whether PET/CT accurately predicts BM involvement in MZL is largely unknown. The Lugano classification supports BM evaluation by PET/CT in HL and DLBCL but acknowledges limited data in other histologies.7 MZL comprises 3 subtypes, each with unique biology, clinical features, and incidence of BM involvement.9...